ImmuCell annual meeting results: directors elected, equity plan and officer exculpation approved

4. To approve an amendment to the Company’s Certificate of Incorporation to reflect certain Delaware law provisions regarding the exculpation of officers: For Against Abstain Broker Non-votes 4,851,019 325,531 11,244 2,209,901 53.62% of total shares outstanding voted in favor. On the basis of this vote, the amendment to the Company’s Certificate of Incorporation to reflect certain Delaware law provisions regarding the exculpation of officers was approved.

1. To elect to one-year terms as Directors of the Company the nominees listed in the Company’s Proxy Statement dated April 24, 2026: For Withheld Broker Non-Votes Gloria J. Basse 5,177,979 9,815 2,209,901 P. Olivier te Boekhorst 5,180,197 7,597 2,209,901 Anthony A. Dimarco 5,179,503 8,291 2,209,901 Gilles Guillemette 5,166,860 20,934 2,209,901 David S. Tomsche 5,173,863 13,931 2,209,901 Kathy V. Turner 5,166,863 20,931 2,209,901 Paul R. Wainman 5,177,135 10,659 2,209,901 On the basis of this vote, each of the seven nominees was elected to a one-year term as a Director of the Company.

5. To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2026: For Against Abstain Broker Non-votes 7,344,196 14,645 38,854 0 99.28% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2026 was ratified.

3. To approve the Company’s 2025 Stock Option and Incentive Plan: For Against Abstain Broker Non-votes 4,689,407 18,453 479,934 2,209,901 90.39% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the matter was approved.

2. To approve a non-binding advisory resolution on the Company’s executive compensation program: For Against Abstain Broker Non-votes 4,793,553 29,155 365,086 2,209,901 92.4% of the shares voting at this meeting in person or by proxy voted in favor. On the basis of this vote, the non-binding advisory resolution on the Company’s executive compensation program was approved.